Unique collaboration between OPO and transplant center initiated in XVIVO’s US clinical trial
The Organ Procurement Organization (OPO) in Michigan has invested in one XPS™ from XVIVO Perfusion in order to facilitate EVLP procedures through collaboration with the three transplant centers in the state. This collaboration is the first of its kind in the USA and it aims to increase the utilization of lungs through the performance of EVLP since one OPO facilitates, coordinate and support multiple lung transplant centers.
University of Michigan and the Michigan OPO, Gift of Life Michigan, are leading the collaboration among the three transplant centers in the area. The collaboration between the OPO who will perfuse the lungs with STEEN Solution™ using the XPS™, and the transplant center that will perform the lung transplant is the first of its kind in the USA. The aim of the collaboration is to increase the utilization of lungs and give transplants to more patients with severe lung disease.
Last week the centers completed their XVIVO Perfusion System (XPS™) training during a two day course. The Michigan centers will start enrolling patients into the NOVEL study in the beginning of 2014. There continues to be a great interest in the USA for the STEEN Solution™ EVLP method, the XPS™ and to participate in the NOVEL study.
"We are pleased that more well-known clinical transplantation centers have joined the NOVEL trial and that the connected OPO has invested in an XPS™. This collaboration is first of its kind in the US and will increase the utilization of lungs and give transplants to more patients with severe lung disease, since one OPO can support multiple transplant centers. This is a very interesting model which has the potential to speed up the introduction of EVLP in the USA and it may become the dominating model in the future" says Dr Magnus Nilsson CEO of XVIVO Perfusion.
December 19, 2013
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59, firstname.lastname@example.org
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
Xvivo Perfusion is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on December 19, 2013 at 2:00 p.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The Xvivo share is listed on NASDAQ OMX First North and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: email@example.com. Website: www.xvivoperfusion.com